Bambusa Therapeutics (BBTX) vs Inhibrx Biosciences (INBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Inhibrx Biosciences is the larger company by market cap ($1.02 billion vs $815.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBTX | INBX |
|---|---|---|
| Share price | $16.00 | $68.97 |
| Market cap | $815.08M | $1.02B |
| 1-day change | +2.89% | -7.21% |
| YTD return | — | -12.70% |
| 1-year return | — | -17.82% |
| EPS (TTM) | $-1.73 | $-9.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.30M |
| Revenue growth (YoY) | — | +550.00% |
| Net income (latest FY) | — | $-140.06M |
| Operating margin | — | -10386.54% |
| Net margin | — | -10773.46% |
| 52-week high | $17.65 | $155.29 |
| 52-week low | $13.60 | $57.30 |
| Distance from 52-week high | -9.35% | -55.59% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +286.65% |
| Average volume | 359.41K | 305.96K |
| Shares outstanding | 50.94M | 14.77M |
| Employees | 26 | 109 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bambusa Therapeutics
BBTX stock →Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 26 employees
About Inhibrx Biosciences
INBX stock →Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
BBTX vs INBX FAQ
Which is bigger, Bambusa Therapeutics or Inhibrx Biosciences?
Inhibrx Biosciences (INBX) is larger, with a market capitalization of $1.02B compared with $815.08M for Bambusa Therapeutics (BBTX).
Are Bambusa Therapeutics and Inhibrx Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.